Clinical trial

Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel

NCT05582538

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2022-12-15

PhasePHASE2

Study timeline

Study start (actual)2022-12-15Date precision: day

Registry last updated2025-08-24

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Triple Negative Breast Cancer Metastaticunresolved

Interventions

CeralasertibDRUG

DurvalumabDRUG · verified · RxNorm: durvalumab

Nab-paclitaxelDRUG

Sponsors & collaborators

IFOM ETS - The AIRC Institute of Molecular Oncologylead sponsor

AstraZenecacollaborator

Mapped research locations

MilanItaly1 NaplesItaly1 PadovaItaly1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05582538 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.